In September 2020, MTPConnect announced the formation of an Australian-first network bringing together key stakeholders to address the impact of antimicrobial resistance (AMR) on human health.
The Australian Antimicrobial Resistance network - AAMRNet – has been established following recommendations in a new report, ‘Fighting Superbugs: A Report on the Inaugural Meeting of Australia’s Antimicrobial Resistance Stakeholders’, also released by MTPConnect and prepared in partnership with Biointelect.
Antimicrobial resistance occurs when microbes such as bacteria become resistant to drugs which once killed them, evolving to become untreatable ‘superbugs’.
Join the AAMRNet, by contacting MTPConnect.
Consortium lead: MTPConnect
Industry contributions by: Pfizer ANZ, CSIRO, MSD Australia, GSK Australia, Botanix Pharmaceuticals, Recce Pharmaceuticals, SpeeDx, Biointelect, Monash Centre to Impact AMR, and Medicines Australia
MTPConnect grant: $300,000
Industry contributions: $780,000
Project duration: September 2020 to June 2022
Additional partners of the AAMRNet include: DMTC, GARDP, AusBiotech, Roche Diagnostics Australia, Menzies School of Health Research, Formulytica, Epichem, BiomeBank, CO-ADD, Monash Biomedicine Discovery Institute and RESULTS International Australia.